Valuation: Tarsus Pharmaceuticals, Inc.

Market Cap 3.43B 2.99B 2.83B 2.57B 4.8B 329B 4.84B 33.84B 13.05B 167B 12.89B 12.61B 536B P/E 2026 *
-36.7x
P/E 2027 * 33.6x
Enterprise Value 3.43B 2.99B 2.83B 2.57B 4.8B 329B 4.84B 33.84B 13.05B 167B 12.89B 12.61B 536B EV / Sales 2026 *
4.8x
EV / Sales 2027 * 3.77x
Free-Float
97.31%
Yield 2026 *
-
Yield 2027 * -
1 day-0.75%
1 week-10.98%
Current month+4.58%
1 month+12.20%
3 months+25.53%
6 months+14.24%
Current year-5.18%
1 week 77.08
Extreme 77.08
83.34
1 month 68.71
Extreme 68.71
91.53
Current year 53.89
Extreme 53.89
91.53
1 year 50.71
Extreme 50.71
91.53
3 years 12.57
Extreme 12.57
91.53
5 years 10.8
Extreme 10.8001
91.53
10 years 10.8
Extreme 10.8001
91.53
Manager TitleAgeSince
Chief Executive Officer 48 01/09/2018
Director of Finance/CFO 64 24/04/2023
Chief Tech/Sci/R&D Officer 47 04/11/2024
Director TitleAgeSince
Chairman 48 02/12/2022
Director/Board Member 71 01/12/2019
Director/Board Member 80 01/01/2017
Date Insider Type Main position Quantity % Market Cap. Importance
04/09/26 Sell

Chief Operating Officer

-4,564 0.0104%
04/09/26 Sell

Chief Executive Officer

-10,000 0.0228%
04/09/26 Sell

Chief Technology Officer

-13,953 0.0318%
Change 5-day change 1-year change 3-year change Capi.($)
-0.75%-10.98%+56.56%+381.04% 3.43B
+0.06%-4.41%+35.28%-5.93% 77.3B
+0.09%-0.22%-14.71%-34.84% 59.52B
+1.29%+3.77%+509.80%+27.08% 57.4B
-0.21%-2.15%-11.88%+25.36% 47.91B
-1.81%-0.39%+0.29%+144.77% 46.2B
-0.07%+1.65%+50.72%-15.22% 31.94B
+2.47%+0.28%+50.05%+99.44% 24.68B
-0.95%-6.09%-1.57%+140.05% 21.08B
-0.05%-3.85%+60.95%+95.99% 15.65B
Average -0.08%-1.96%+73.55%+85.77% 38.51B
Weighted average by Cap. -0.06%-0.98%+89.66%+38.06%

Financials

2026 *2027 *
Net sales 715M 623M 590M 534M 1B 68.58B 1.01B 7.05B 2.72B 34.78B 2.68B 2.63B 112B 910M 794M 752M 680M 1.27B 87.33B 1.28B 8.97B 3.46B 44.29B 3.42B 3.34B 142B
Net income -95.74M -83.48M -79.06M -71.54M -134M -9.18B -135M -944M -364M -4.66B -360M -352M -14.95B 116M 101M 95.72M 86.62M 162M 11.12B 163M 1.14B 441M 5.64B 435M 426M 18.1B
Net Debt - -
Logo Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company's lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. It is investigating the development of its product candidates to address targeted diseases with medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction. It is also developing IRX-101, an investigational ocular antiseptic.
Employees
370
Date Price Change Volume
16/09/26 $77.64 -0.75% 650,075
15/09/26 $78.23 -2.15% 623,985
14/09/26 $79.95 +0.81% 693,703
11/09/26 $79.31 -2.23% 490,786
10/09/26 $81.12 -1.99% 403,284
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
77.64USD
Average target price
97.67USD
Spread / Average Target
+25.79%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TARS Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!